STOCK TITAN

Pfizer Inc. - PFE STOCK NEWS

Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.

Pfizer Inc. (PFE), headquartered at The Spiral in Manhattan, New York City, is a leading American multinational pharmaceutical and biotechnology corporation established in 1849 by Charles Pfizer and his cousin Charles F. Erhart. Pfizer stands as one of the world's largest pharmaceutical companies, with annual sales nearing $50 billion, excluding COVID-19 product sales.

Pfizer's core business revolves around the development, manufacturing, and global distribution of prescription drugs and vaccines. Its top-selling products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. These products contribute significantly to Pfizer's global sales, with nearly 50% of revenues coming from international markets, and emerging markets playing a crucial role.

In recent news, Pfizer continues to make strides in cancer treatment through its collaboration with Astellas and Merck. A key focus has been on the promising cancer therapeutic combinations involving PADCEV™ (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab), targeting metastatic urothelial cancer. This collaboration underscores Pfizer's commitment to advancing cancer treatments and improving patient outcomes worldwide.

Financially, Pfizer remains robust, continually investing in research and development to innovate and expand its portfolio of treatments addressing unmet medical needs. Strategic partnerships and collaborations further enhance its position in the market, ensuring a steady pipeline of new and effective therapeutic solutions.

With a rich history and a steadfast commitment to healthcare innovation, Pfizer Inc. continues to be a significant player in the pharmaceutical industry, dedicated to improving global health through advanced medical research and groundbreaking therapies.

Rhea-AI Summary

The FDA has granted full approval for TIVDAK® for the treatment of recurrent or metastatic cervical cancer. TIVDAK is the first antibody-drug conjugate with positive overall survival data for patients with previously treated disease. The approval is based on results from a Phase 3 study showing an overall survival benefit compared to chemotherapy. The safety profile of TIVDAK was consistent with known information, with no new safety issues identified. Common adverse reactions included decreased hemoglobin, peripheral neuropathy, and conjunctival adverse reactions. The approval of TIVDAK brings new treatment options for patients with advanced cervical cancer and addresses the high unmet need in this patient population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
none
-
Rhea-AI Summary

Genmab A/S and Pfizer Inc. announced that the U.S. FDA has approved TIVDAK® for recurrent or metastatic cervical cancer treatment, converting its accelerated approval to a full approval. This is the first ADC with positive overall survival data in this patient population. The approval is based on Phase 3 data showing a 30% risk reduction in death compared to chemotherapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
-
Rhea-AI Summary

Pfizer (PFE) Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
Pfizer Inc. (NYSE: PFE) is presenting more than 50 abstracts and 11 oral presentations at the annual ASCO meeting, showcasing its robust portfolio of approved and pipeline therapies and highlighting Pfizer's efforts to accelerate breakthrough medicines in Oncology. Key research includes data from the LORBRENA CROWN study and Phase 3 ECHELON-3 study of ADCETRIS, demonstrating overall survival benefit for a type of lymphoma. Pfizer will also present Phase 1 data for several priority pipeline therapies across different tumor areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
none
Rhea-AI Summary
Pfizer's BEQVEZ gene therapy for hemophilia B has been approved by the FDA, providing a one-time treatment option for adults. The therapy has shown significant reduction in bleeds post-treatment compared to standard care, potentially avoiding years of treatment burden. Pfizer is also launching an innovative warranty program to ensure durability of patient response to treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
-
Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) declares a $0.42 dividend per share for the second quarter of 2024, marking the 342nd consecutive quarterly dividend paid by the company. The dividend is payable on June 14, 2024, to shareholders of record as of May 10, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.84%
Tags
dividends
-
Rhea-AI Summary
Pfizer's EMBLAVEO® receives approval from the European Commission for treating serious infections caused by multidrug-resistant bacteria, including metallo-β-lactamase-producing bacteria. The antibiotic combination is the first of its kind in the EU and offers hope to patients facing treatment options. The approval is based on successful Phase 3 studies showing efficacy, safety, and tolerability in treating Gram-negative bacterial infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) announces its virtual-only 2024 Annual Meeting of Shareholders, providing shareholders with comparable rights to an in-person meeting. Shareholders can access the meeting online, ask questions, and vote. The meeting details and registration information are available on the company's website. Shareholders can participate in real-time discussions and submit questions in advance. Both registered and beneficial shareholders can vote during the meeting, with some beneficial owners needing to pre-register. Guests can listen to the meeting without a control number. A replay of the webcast will be available for one year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
conferences
-
Rhea-AI Summary
Pfizer Inc. announced positive top-line immunogenicity and safety data from the Phase 3 clinical trial of ABRYSVO in adults aged 18 to 59 at risk of severe RSV disease. The vaccine showed non-inferior immune response compared to older adults, with well-tolerated and consistent safety profiles. Pfizer aims to seek regulatory approval for ABRYSVO in the 18 to 59 age group, potentially addressing a significant unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
-
Rhea-AI Summary
ALTIVIA appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager. Both bring extensive experience in the chemicals industry and will contribute to ALTIVIA's growth and operational excellence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
management
Rhea-AI Summary
ViiV Healthcare, in collaboration with Pfizer and Shionogi, receives FDA approval for Dovato, the first oral, two-drug, single-tablet regimen for adolescents aged 12 and older living with HIV. The expanded indication aims to address the treatment gaps in young HIV patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags

FAQ

What is the current stock price of Pfizer (PFE)?

The current stock price of Pfizer (PFE) is $26.22 as of January 15, 2025.

What is the market cap of Pfizer (PFE)?

The market cap of Pfizer (PFE) is approximately 148.9B.

What is Pfizer Inc. known for?

Pfizer Inc. is known for its development, manufacturing, and distribution of prescription drugs and vaccines, including Prevnar 13, Ibrance, and Eliquis.

Where is Pfizer's headquarters located?

Pfizer's headquarters are located at The Spiral in Manhattan, New York City.

How much does Pfizer make annually?

Pfizer's annual sales are close to $50 billion, excluding COVID-19 product sales.

What are some of Pfizer's top-selling products?

Some of Pfizer's top-selling products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis.

What is the significance of Pfizer's international sales?

Pfizer's international sales represent nearly 50% of its total sales, with emerging markets being a major contributor.

What recent collaborations has Pfizer been involved in?

Pfizer has recently been involved in collaborations with Astellas and Merck to develop and commercialize cancer treatments like PADCEV™ and KEYTRUDA®.

When was Pfizer founded?

Pfizer was founded in 1849 by Charles Pfizer and Charles F. Erhart.

What is Pfizer's approach to innovation?

Pfizer continually invests in research and development to innovate and expand its portfolio of treatments addressing unmet medical needs.

How does Pfizer contribute to cancer treatment?

Pfizer contributes to cancer treatment through its development of innovative therapies and strategic collaborations, notably involving PADCEV™ and KEYTRUDA®.

What role do strategic partnerships play for Pfizer?

Strategic partnerships enhance Pfizer's market position, ensuring a steady pipeline of new and effective therapeutic solutions.
Pfizer Inc.

NYSE:PFE

PFE Rankings

PFE Stock Data

148.90B
5.66B
0.05%
67.79%
1.51%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
NEW YORK